The discovery of NTCP as HBV entry receptor has meanwhile allowed to engineer NTCP-expressing HepG2 cells that are susceptible to HBV infection, albeit infection efficiency is very limited, with no net amplification of the input virus. This evidence concerns the gene SLC10A1 and infection.